News
Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...
Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback